• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于新机制的类胰蛋白酶失活剂。含磺甲基取代间氨基苯甲酸残基的功能化环肽对尿激酶的选择性失活。

New mechanism-based inactivators of trypsin-like proteinases. Selective inactivation of urokinase by functionalized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid residue.

作者信息

Wakselman M, Xie J, Mazaleyrat J P, Boggetto N, Vilain A C, Montagne J J, Reboud-Ravaux M

机构信息

CNRS-CERCOA, Thiais, France.

出版信息

J Med Chem. 1993 May 28;36(11):1539-47. doi: 10.1021/jm00063a004.

DOI:10.1021/jm00063a004
PMID:8496923
Abstract

In order to obtain selective suicide substrates of trypsin-like proteases including plasminogen activators, plasmin, and thrombin, a series of cyclopeptides cyclo[Arg or Lys-aB(CH2X)-Gly4], in which a substituted o- or m-aminobenzoyl group constitutes a latent electrophile, have been prepared. Treatment of the corresponding phenyl ethers cyclo[P1-aB(CH2OC6H5)-Gly4] with HBr/HOAc or R1R2S/TFA gives the bromides (X = Br) or the sulfonium salts (X = +SR1R2 with R1 = R2 = Me or R1 = Me and R2 = C6H5), respectively. These water-soluble cyclopeptides behave as time-dependent inhibitors of bovine trypsin and human urokinase (u-PA) but have no effect on tissue plasminogen activator (t-PA) and no or poor effect on plasmin and thrombin. The compounds containing a m-aminobenzoic acid residue are more efficient inactivators than their anthranilic analogues. The kinetic criteria expected for a suicide inhibition are met. A mechanism of inhibition involving the formation of a quinonimmonium methide intermediate is proposed. The activity of the inhibitors is very sensitive to the nature of the X benzylic substituent. An increased efficiency for the inactivation of human urokinase is observed with the sulfonium salts. The selectivity of the inactivation of u-PA compared to t-PA could be of therapeutical significance in controlling cell proliferation and invasion.

摘要

为了获得包括纤溶酶原激活剂、纤溶酶和凝血酶在内的胰蛋白酶样蛋白酶的选择性自杀底物,已制备了一系列环肽环[精氨酸或赖氨酸-αB(CH₂X)-甘氨酸₄],其中取代的邻氨基苯甲酰基或间氨基苯甲酰基构成潜在亲电试剂。用HBr/HOAc或R₁R₂S/TFA处理相应的苯醚环[P₁-αB(CH₂OC₆H₅)-甘氨酸₄],分别得到溴化物(X = Br)或锍盐(X = +SR₁R₂,其中R₁ = R₂ = 甲基或R₁ = 甲基且R₂ = 苯基)。这些水溶性环肽表现为牛胰蛋白酶和人尿激酶(u-PA)的时间依赖性抑制剂,但对组织纤溶酶原激活剂(t-PA)无作用,对纤溶酶和凝血酶无作用或作用较弱。含有间氨基苯甲酸残基的化合物比其邻氨基苯甲酸类似物是更有效的失活剂。满足自杀抑制预期的动力学标准。提出了一种涉及形成醌亚甲基中间体的抑制机制。抑制剂的活性对X苄基取代基的性质非常敏感。观察到锍盐对人尿激酶失活的效率增加。与t-PA相比,u-PA失活的选择性在控制细胞增殖和侵袭方面可能具有治疗意义。

相似文献

1
New mechanism-based inactivators of trypsin-like proteinases. Selective inactivation of urokinase by functionalized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid residue.基于新机制的类胰蛋白酶失活剂。含磺甲基取代间氨基苯甲酸残基的功能化环肽对尿激酶的选择性失活。
J Med Chem. 1993 May 28;36(11):1539-47. doi: 10.1021/jm00063a004.
2
A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.一种环肽类自杀底物优先使尿激酶型纤溶酶原激活剂失活。
Biochem Biophys Res Commun. 1991 Jul 15;178(1):352-9. doi: 10.1016/0006-291x(91)91821-s.
3
Guanidinophenyl-substituted enol lactones as selective, mechanism-based inhibitors of trypsin-like serine proteases.胍基苯基取代的烯醇内酯作为胰蛋白酶样丝氨酸蛋白酶的选择性、基于机制的抑制剂。
J Med Chem. 1992 Oct 30;35(22):4150-9. doi: 10.1021/jm00100a021.
4
[Synthetic inhibitors targeting serine and aspartic acid proteases].[靶向丝氨酸和天冬氨酸蛋白酶的合成抑制剂]
J Pharm Belg. 1996 May-Jun;51(3):161-4.
5
Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.设计对丝氨酸蛋白酶190(Ser190)样胰蛋白酶样丝氨酸蛋白酶药物靶点的S1位点具有高度选择性的抑制剂。
Chem Biol. 2001 Nov;8(11):1107-21. doi: 10.1016/s1074-5521(01)00084-9.
6
Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A.环仿酰胺A对凝血酶及其他胰蛋白酶样丝氨酸蛋白酶的抑制作用
Thromb Res. 1993 Apr 15;70(2):173-90. doi: 10.1016/0049-3848(93)90158-k.
7
Amiloride selectively inhibits the urokinase-type plasminogen activator.
FEBS Lett. 1987 Apr 6;214(1):187-91. doi: 10.1016/0014-5793(87)80039-x.
8
Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones.三肽精氨酰氯甲基酮和赖氨酰氯甲基酮对类胰蛋白酶丝氨酸蛋白酶的抑制作用。
Thromb Res. 1984 Jun 1;34(5):431-7. doi: 10.1016/0049-3848(84)90247-0.
9
Tripeptides with non-code amino acids as potential serine proteases inhibitors.具有非编码氨基酸的三肽作为潜在的丝氨酸蛋白酶抑制剂。
J Enzyme Inhib Med Chem. 2013 Jun;28(3):639-43. doi: 10.3109/14756366.2011.651463. Epub 2012 Feb 3.
10
Polyphenol fatty acid esters as serine protease inhibitors: a quantum-chemical QSAR analysis.多酚脂肪酸酯作为丝氨酸蛋白酶抑制剂:量子化学定量构效关系分析。
J Enzyme Inhib Med Chem. 2012 Dec;27(6):800-9. doi: 10.3109/14756366.2010.616860. Epub 2011 Oct 10.

引用本文的文献

1
Reversible covalent direct thrombin inhibitors.可逆性共价直接凝血酶抑制剂。
PLoS One. 2018 Aug 2;13(8):e0201377. doi: 10.1371/journal.pone.0201377. eCollection 2018.
2
Dual function inhibitors of relevance to chronic obstructive pulmonary disease.与慢性阻塞性肺疾病相关的双重功能抑制剂。
Bioorg Med Chem Lett. 2011 May 15;21(10):3177-80. doi: 10.1016/j.bmcl.2010.12.033. Epub 2010 Dec 10.
3
Effects of structure on inhibitory activity in a series of mechanism-based inhibitors of human neutrophil elastase.一系列人中性粒细胞弹性蛋白酶的基于机制抑制剂中结构对抑制活性的影响。
Bioorg Med Chem. 2010 Sep 15;18(18):6646-50. doi: 10.1016/j.bmc.2010.07.071. Epub 2010 Aug 5.
4
Mechanism-based inhibitors of serine proteases with high selectivity through optimization of S' subsite binding.通过优化S'亚位点结合实现高选择性的基于机制的丝氨酸蛋白酶抑制剂
Bioorg Med Chem. 2009 May 15;17(10):3536-42. doi: 10.1016/j.bmc.2009.04.011. Epub 2009 Apr 12.
5
X-ray snapshot of the mechanism of inactivation of human neutrophil elastase by 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives.1,2,5-噻二唑烷-3-酮1,1-二氧化物衍生物使人类中性粒细胞弹性蛋白酶失活机制的X射线快照
J Med Chem. 2008 Apr 10;51(7):2003-8. doi: 10.1021/jm700966p. Epub 2008 Mar 5.
6
Protease inhibitors and their peptidomimetic derivatives as potential drugs.蛋白酶抑制剂及其拟肽衍生物作为潜在药物。
Pharmacol Ther. 2007 Feb;113(2):354-68. doi: 10.1016/j.pharmthera.2006.09.001. Epub 2006 Sep 22.